| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18944 R80578 |
Meng_Taiwan (Controls unexposed, sick), 2026 | Developmental Coordination Disorder - At least 2 diagnoses on different dates ICD-9 and ICD-10: F70.xx-F79.xx - Follow up: between 6 and 12 years | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Paternal ASMs: monotherapy | 1.09 [0.57;2.09] | 10/543 4,864/500,498 | 4,874 | 543 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18948 R80594 |
Razaz_Sweden, 2026 | Intellectual disability (ID) - One diagnosis ICD-10 code for ID: F70– F79 - Median age at the end of follow-up: 6.6 years | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | exposed to other treatment, sick | Adjustment: Yes Paternal ASMs: monotherapy | 1.20 [0.65;2.21] | 22/1,500 33/2,906 | 55 | 1,500 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18654 R79312 |
Botton, 2025 | Intellectual Developmental Disorder - ICD10: F70-F79 - Median follow up (years): 11.9 (IQR [10.3 - 13.3]) for valproate; 11.2 (IQR [9.9 - 12.8]) for control | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | retrospective cohort (claims database) | exposed to other treatment, sick | Adjustment: Yes Paternal ASMs: monotherapy | 2.07 [0.78;5.53] | 25/3,484 5/2,041 | 30 | 3,484 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18646 R79313 |
Christensen (Controls exposed to LTG/LEV), 2024 | Intellectual disability - ICD-10 codes F70-79 - Median age [IQR] age at the end of follow-up: 10.6 [5.4-15.0] years for valproate; 5.5 [2.7-9.3] years for controls | Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception) | population based cohort retrospective | exposed to other treatment, sick | Adjustment: Yes Paternal ASMs: monotherapy | 1.85 [0.72;4.76] | 21/961 7/1,401 | 28 | 961 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.35 [0.93;1.95] | 4,987 | 6,488 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls exposed to LTG/LEV;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded